April 18, 2024
April 11, 2024
March 28, 2024
March 25, 2024
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
March 21, 2024
March 13, 2024
March 12, 2024
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
February 29, 2024
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 27, 2024
February 22, 2024